| Not Yet Recruiting | A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell NCT07498465 | Children's Oncology Group | Phase 1 |
| Recruiting | A Study of Revumenib and Mezigdomide in People With Leukemia NCT07356154 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Le NCT07216443 | Orca Biosystems, Inc. | Phase 2 |
| Recruiting | Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT NCT06551584 | Stanford University | Phase 1 |
| Recruiting | Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell NCT06928662 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579 | Vironexis Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic NCT07256210 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2 |
| Recruiting | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblasti NCT06390319 | St. Jude Children's Research Hospital | Phase 2 |
| Recruiting | Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemi NCT06289673 | St. Jude Children's Research Hospital | Phase 4 |
| Recruiting | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hig NCT06013423 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagno NCT06034470 | Fred Hutchinson Cancer Center | Phase 1 |
| Recruiting | Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma NCT05602194 | Children's Oncology Group | Phase 3 |
| Active Not Recruiting | Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, a NCT05457556 | Children's Oncology Group | Phase 3 |
| Recruiting | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Le NCT05327894 | Princess Maxima Center for Pediatric Oncology | Phase 3 |
| Recruiting | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies NCT05476770 | Therapeutic Advances in Childhood Leukemia Consortium | Phase 1 |
| Recruiting | Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed NCT04872790 | OHSU Knight Cancer Institute | Phase 1 |
| Suspended | Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) NCT05322850 | University of Florida | Phase 1 / Phase 2 |
| Active Not Recruiting | Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic NCT05316701 | Orca Biosystems, Inc. | Phase 3 |
| Completed | Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Pat NCT05433532 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With NCT04726241 | PedAL BCU, LLC | Phase 1 / Phase 2 |
| Recruiting | Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or M NCT04872478 | Meryx, Inc. | Phase 1 |
| Completed | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia NCT05326516 | Syndax Pharmaceuticals | Phase 1 |
| Recruiting | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms NCT04797767 | University of Washington | Phase 1 / Phase 2 |
| Active Not Recruiting | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide NCT04904588 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Unknown | Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia NCT04762485 | The First Affiliated Hospital of Soochow University | Phase 1 / Phase 2 |
| Recruiting | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hemat NCT04195633 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/R NCT03957915 | Institut Paoli-Calmettes | EARLY_Phase 1 |
| Active Not Recruiting | Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting NCT04128501 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation NCT04065399 | Syndax Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenoty NCT03959085 | Children's Oncology Group | Phase 3 |
| Recruiting | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia NCT04067336 | Kura Oncology, Inc. | Phase 1 / Phase 2 |
| Recruiting | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Bloo NCT03779854 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation NCT03843528 | Johns Hopkins All Children's Hospital | Phase 1 |
| Recruiting | A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies NCT03802695 | Orca Biosystems, Inc. | Phase 1 |
| Unknown | Management of Mixed-Phenotype Acute Leukemia in the East of France NCT03599869 | Central Hospital, Nancy, France | — |
| Recruiting | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After NCT03326921 | Fred Hutchinson Cancer Center | Phase 1 |
| Terminated | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed NCT03404193 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, A NCT03128034 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders NCT03198234 | Roncarolo, Maria Grazia, MD | Phase 1 |
| Active Not Recruiting | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromoso NCT03007147 | Children's Oncology Group | Phase 3 |
| Completed | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene NCT02828358 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS NCT02921061 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Di NCT02135874 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Ly NCT01887587 | Ehab L Atallah | Phase 1 |
| Completed | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099 | Fred Hutchinson Cancer Center | Phase 2 |
| Temporarily Not Available | Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies NCT07346105 | Orca Biosystems, Inc. | — |